SCHEMBL3049199

SCHEMBL3049199

COc1cc2c(cc1S(N)(=O)=O)CCN(Cc1cccc(Oc3ccccc3)c1)C2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REV1 Q9UBZ9 1/20 0.53
KDM4E B2RXH2 3/20 0.53
TDP1 Q9NUW8 2/20 0.53
ABCB1 P08183 5/20 0.52
CA2 P00918 2/20 0.50
CA9 Q16790 2/20 0.50
DHCR7 Q9UBM7 1/20 0.49
CHRM2 P08172 1/20 0.49
HTR1A P08908 1/20 0.49
CHRM3 P20309 1/20 0.49
DRD4 P21917 1/20 0.49
ADRA1D P25100 1/20 0.49
HTR2C P28335 1/20 0.49
ADRA1A P35348 1/20 0.49
ADRA1B P35368 1/20 0.49
DRD3 P35462 1/20 0.49
HTR2B P41595 1/20 0.49
SLC6A3 Q01959 1/20 0.49
TMEM97 Q5BJF2 1/20 0.49
SIGMAR1 Q99720 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3042196 0.92 DHCR7 (0.58) REV1KDM4ETDP1ABCB1CA2
SCHEMBL3061675 0.90 REV1 (0.61) REV1KDM4ETDP1ABCB1CA2
SCHEMBL3055597 0.89 REV1 (0.51) REV1KDM4ETDP1ABCB1CA2
SCHEMBL5130886 0.88 REV1 (0.67) REV1KDM4ETDP1ABCB1DHCR7
SCHEMBL3061514 0.88 CA2 (0.49) REV1KDM4ETDP1ABCB1CA2
SCHEMBL3052573 0.87 KDM4E (0.51) REV1KDM4ETDP1ABCB1CA2
SCHEMBL3064367 0.87 CA2 (0.48) REV1KDM4ETDP1ABCB1CA2
SCHEMBL5128393 0.87 REV1 (0.69) REV1KDM4ETDP1ABCB1DHCR7
SCHEMBL3059191 0.86 KDM4E (0.54) REV1KDM4ETDP1ABCB1CA2
SCHEMBL3060196 0.86 KDM4E (0.54) REV1KDM4ETDP1ABCB1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394825-B2 Compound STERIX LIMITED (GB) 2013-03-12 US claimed
US-20100222299-A1 COMPOUND STERIX LIMITED (GB) 2010-09-02 US claimed
US-8394825-B2 Compound STERIX LIMITED (GB) 2013-03-12 US disclosed
US-20100222299-A1 COMPOUND STERIX LIMITED (GB) 2010-09-02 US disclosed
EP-2155192-A2 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS Sterix Limited (GB) 2010-02-24 EP disclosed
WO-2008117061-A2 TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS STERIX LIMITED (GB) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222299-A1 COMPOUND MKI67, VHL, MYC REV1 1520/4885KDM4E 1083/4885TDP1 4235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.